Cargando…

Genetic Polymorphism rs6505162 in MicroRNA-423 May Not Be Associated with Susceptibility of Breast Cancer: A Systematic Review and Meta-Analysis

BACKGROUND: MicroRNA-423 (miR-423) rs6505162 polymorphism is found to be associated with breast cancer (BC) risk. However, the results were inconsistent. This study meta-analyzed the literature on possible association between rs6505162 polymorphism and BC risk. METHODS: PubMed, Embase, Google Schola...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zhi, Wang, Jin, Chen, Hui-bing, Guo, Xiao-Mei, Chen, Xiao-Ping, Wang, Meng, Dong, Li-Juan, Zhang, Min-Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641987/
https://www.ncbi.nlm.nih.gov/pubmed/34868312
http://dx.doi.org/10.1155/2021/3003951
Descripción
Sumario:BACKGROUND: MicroRNA-423 (miR-423) rs6505162 polymorphism is found to be associated with breast cancer (BC) risk. However, the results were inconsistent. This study meta-analyzed the literature on possible association between rs6505162 polymorphism and BC risk. METHODS: PubMed, Embase, Google Scholar, and the Chinese National Knowledge Infrastructure (CNKI) databases were systematically searched to identify relevant studies. Meta-analyses were performed to examine the association between rs6505162 polymorphism and BC. RESULTS: None of the five genetic models suggested a significant association between rs6505162 polymorphism and BC risk: allelic model, OR 1.02, 95% CI 0.18–1.28, P=0.85; recessive model, OR 0.99, 95% CI 0.72–1.38, P=0.97; dominant model, OR 0.93, 95% CI 0.72–1.21, P=0.60; homozygous model, OR 1.04, 95% CI 0.66–1.65, P=0.87; and heterozygous model, OR 1.07, 95% CI 0.90–1.28, P=0.45. Similar results were obtained in subgroup analyses of Asian, Chinese, and Caucasian patients. CONCLUSION: The available evidence suggests no significant association between rs6505162 polymorphism and BC risk. These conclusions should be verified in large, well-designed studies.